(OTCQB:RGBP-RGBPP) Regen BioPharma, Inc.
Regen entered into a Collaborative Agreement With (LLY) Eli Lilly & Company June 30, 2016 to Develop Cancer Therapies & Treat Autoimmunity Diseases.
Eli Lilly & Company Reserves the Right to License or Buy Regens Developed Compounds and/or New Drugs.
The company is focused on the immunology and immunotherapy spaces. They are now rapidly advancing novel technologies through Pre-Clinical & Phase I/II clinical trials. Regen is concentrating on small molecule therapies for treating cancers and autoimmune disorders.
While it has taken time, testing thousands of compounds provided by Eli Lilly, they have identified a handful of compounds representing three different structural classes that inhibit in their primary screening assays.
Recently Regen has reported the Success of its NR2F6 Small Molecule Screening Program for Cancer. They Have Identified a Series of Small Molecule Drugs That Can Potentially Be Developed to Treat various cancers.
The Novel Chemical Compound Drugs Show the Potential to Manipulate and Potentially Turn Cancer Cells Into Normal Cells. They Aim to Identify Antagonists of NR2F6 to Unleash the Cancer-Killing Potential of Patient's Own Immune Systems.
According to a report published by Progressive Markets, the cancer immunotherapy market was valued at USD 57.2 Billion in 2017 and is expected to reach USD 166.7 Billion by 2025 while growing at a compound annual growth (OTC:CAGR) of 14.42%. The increasing spending on R&D activities for cancer immunotherapy, growing occurrence of cancer and the rise in approvals for the clinical trials are the main drivers of the market. Additionally, the number of people who have cancer is rising rapidly. According to a report released by the World's Health Organization's International Agency for Research on Cancer, cancer is estimated to cause 9.6 Million deaths and have 18.1 Million new cases in 2018. Cancer immunotherapy is one of the treatment types for cancer and has gained widespread importance in recent years. Regen BioPharma, Inc. (OTC : RGBP ), Palatin Technologies, Inc. (NYSE :PTN ), Agenus Inc. (NASDAQ : AGEN ), BioLineRx Ltd. (NASDAQ : BLRX ), Ziopharm Oncology, Inc. (NASDAQ : ZIOP )
Regen also recently announced its success treating Autoimmune diseases like Lupus. The NR2F6 program at Regen aims to identify not just antagonists in an effort to unleash the cancer-killing potential of a patient's own immune system, but also identifying agonists as well which should suppress immune systems diseases where the immune system is over-activated, such as autoimmunity.
They have exibited a dose-dependent inhibitory effect on NR2F6 without cytotoxicity. Their lead drug RG-NAE005 showed no toxicity in doses up to 2,000mg/kg. They also saw no toxicity in repeated doses of 400mg/kg which indicates it should be safe in animals as they begin the efficacy phase.
Drug safety is always the number one concern. they were very pleased to see it was safe in Mice. It's another major milestone Regen has passed with this drug.
Ongoing Clinical Trials
Breast Cancer – dCellVax - IND #16200
CellVax is a dendritic cell based immunotherapy that stimulates the patient’s immune system through a process called “gene silencing.”
- 10 advanced breast cancer patients
- Efficacy endpoints at 6 and 12 months
- Establishment of safety will allow for rapid expansion of patient numbers
- Currently addressing FDA questions with Dr. Santosh Kesari, head of UCSD Neuro-Oncology program
- Other Cancers being addressed are: Lung, Bladder, Liver & Leukemia
Aplastic Anemia Stem Cell Therapy – HemaXellerate – IND #15376 CLEARED TO PROCEED TO PHASE I / II CLINICAL TRIALS
HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients whose bone marrow is not properly functioning.
- Fat stem cell based product to treat bone marrow that has been damaged
- Bone marrow damage occurs from radiation, chemo, or chronic conditions
- HemaXellerate uses patient’s own fat as source of endothelial cells to heal damaged bone marrow
- United States Food and Drug Administration Investigational New Drug Application cleared (IND #15376)
Hematopoietic Stem Cell Transplantation (OTCPK:HSCT) Market Expansion To 2025 By Key Players Pluristem Therapeutics Inc., CellGenix Technologie Transfer GmbH, Kite Pharma Inc., Regen Biopharma Inc., BiolineRx
Hematopoietic Stem Cell Transplantation (HSCT) Market Expansion To 2025 By Key Players Pluristem Therapeutics Inc., CellGenix Technologie Transfer GmbH, Kite Pharma Inc., Regen Biopharma Inc., BiolineRx - Fair Reporter
These are exciting times at Regen. While the company is small, it has huge potential going forward. They could be an attractive merge-buy out target.
Regen has the potential to trade at much higher prices. It trades up, down, around but does display nice upward trends at times which was evident recently. Regen realized a 100% gain over a short period beginning on 9/4/18. Since it has retraced, likely some taking profits, and could be debt equity used for financing that matured. Overall at the open 9/21/18 the share price at $0.0158 was still up 45% since 9/4/2018. The stock has also show better liquidity since mid August.
Take some time, do your due diligence, this company with what they have achieved, and what seems to be a very bright future going forward, looks to be a diamond in the rough. Ask yourself? Why would Eli Lilly waste their time?
For All The News/PR's/Filings Visit: https://www.regenbiopharmainc.com
https://www.otcmarkets.com/stock/RGBP/overview
You can also visit our site for daily updates on (OTCQB:OTCPK:RGBP)
https://www.smallcapsolutions.com
Robert E. Kreh – Principal
Small Cap Solutions, LLC
robkreh@smallcapsolutions.com
(443) 567-2609
https://www.smallcapsolutions.com
(OTCQB:RGBP) Disclaimer: You are receiving this because you have requested the information contained in this email, and/or have expressed an interest recently, or in the past to be included in such emails. And/or have requested information/news/updates for Regen BioPharma, Inc. This profile has been compiled by Small Cap Solutions, LLC based on information from the company believed to be true/factual. This profile is not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Act of 1995. Actual results could differ materially from the statements either expressed or implied herein. Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at . Small Cap Solutions, LLC has received payment in cash from Value Quest, Inc. for investor relations services rendered for Regen BioPharma, Inc. . Additional inquiries are available by email to or in writing to Small Cap Solutions, LLC 303 Joppa Crossing Ct (Suite #1) Joppa, Md. 21085 This is not a solicitation to buy or sell securities. To "unsubscribe to this mailing list, please reply "unsubscribe" to this message.
Disclaimer: All Micro/Small Cap Company(ies) profile() are/have been compiled by Small Cap Solutions, LLC based on information believed to be true and gathered either from client companies and/or third party('s)/web sites. These profiles are not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and has been prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from the statements either expressed or implied herein. Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at and/or Small Cap Solutions, LLC may receive cash or stock from client companies for investor relations services rendered.
Small Cap Solutions, LLC and/or its Principal/Employees are not registered Broker(S)/Broker Dealer with FINRA or the SEC. Small Cap Solutions, LLC does not make any buy/sell recommendations at any time, but may state their opinion on companies, etc. That is not meant to be a recommendation. All information disseminated by Small Cap Solutions, LLC is believed to be true and public. Additional inquiries available by email to or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message.